文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

意大利近二十年HIV耐药流行率大幅下降但多药耐药仍需关注

HIV MDR is still a relevant issue despite its dramatic drop over the years.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该研究评估了意大利1999—2018年接受抗逆转录病毒治疗(ART)失败的HIV-1感染者分离株的耐药流行率及治疗相关性。对至少一类药物耐药的比例从≤2001年的84.6%降至2010年的43.6%(P<0.001),2010—2018年稳定在约40%,对三类及以上药物耐药的比例稳定在约5%。在1827例治疗失败且有随访的患者中,基因型指导治疗后1年病毒学成功(VS)概率为87.6%,但三类及以上累计耐药且接受低活性方案者VS概率最低(62.6%)。

要点

  • 意大利HIV-1失败株对至少一类药物耐药从84.6%降至约40%后趋稳,三类及以上耐药约5%。
  • 三类及以上累计耐药且接受低活性方案者1年病毒学成功概率最低(62.6%)。
  • 多药耐药(MDR)仍存在,需合理的诊断与治疗管理策略。

核心结论

  • 意大利近二十年HIV-1治疗失败株耐药大幅下降,但对三类及以上药物耐药仍低水平存在,MDR管理仍需理性、细致的诊断与治疗策略。

研究设计与样本

  • 回顾性分析意大利1999—2018年ART经治HIV-1感染者分离株的耐药动态。
  • 评估对一、二、三类及以上药物类别的耐药,并按累计类别耐药与累计基因型敏感评分(Stanford HIV_DB算法)评估最新换药后的病毒学成功。

主要发现

  • 对至少一类药物耐药从≤2001年的84.6%降至2010年的43.6%(P<0.001),2010—2018年维持在约40%。
  • 对三类及以上药物耐药比例稳定在约5%。
  • 2008年后整合酶抑制剂耐药从5.6%升至2018年的9.7%,在三类及以上耐药株中占34.7%(P<0.001)。
  • 1827例失败且有随访患者中,基因型指导治疗开始后1年VS概率为87.6%。
  • 三类及以上累计耐药且接受低活性方案者VS概率为62.6%(P<0.001),其他患者≥81.8%。

关键数值与推荐

  • 对至少一类药物耐药:≤2001年84.6%,2010年43.6%,2010—2018年约40%。
  • 对三类及以上药物耐药:约5%。
  • 整合酶抑制剂耐药:2008年5.6%升至2018年9.7%;在三类及以上耐药株中为34.7%。
  • 1年VS概率:总体87.6%;三类及以上耐药且低活性方案62.6%;其他患者≥81.8%。

临床怎么用

  • 对ART失败者应结合累计耐药史与基因型敏感评分选择活性方案。
  • 三类及以上累计耐药且方案活性不足者病毒学成功概率低,需更审慎的换药与管理。

局限性

  • 为意大利单国数据,外推需谨慎。
  • 部分分析基于可获得随访的失败患者,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the prevalence and therapeutic relevance of drug resistance among isolates from ART-experienced HIV-1-infected patients over the past two decades in Italy. METHODS: Dynamics of resistance to one, two and three or more antiretroviral classes were evaluated from 1999-2018. Virological success (VS) after the latest therapy switch was evaluated according to cumulative class resistance and cumulative genotypic susceptibility score (Stanford HIV_DB algorithm). RESULTS: Among 13 663 isolates (from 6739 patients), resistance to at least one drug class decreased sharply from 1999 to 2010 (≤2001, 84.6%; 2010, 43.6%; P < 0.001), then remained relatively constant at ∼40% during 2010-18, with the proportion of resistance to three or more classes also stable (∼5%). After 2008, integrase inhibitor resistance slightly increased from 5.6% to 9.7% in 2018 and contributed to resistance, particularly in isolates with resistance to three or more classes (one class, 8.4%; two classes, 15.3%; three or more classes, 34.7%, P < 0.001). Among 1827 failing patients with an available follow-up, by 1 year after genotype-guided therapy start the probability of VS was 87.6%. Patients with cumulative resistance to three or more classes and receiving a poorly active regimen showed the lowest probability (62.6%) of VS (P < 0.001) compared with all other patients (≥81.8%). By Cox regression analysis, cumulative MDR and receiving poorly active antiretroviral regimens were associated with a lower hazard of VS compared with those without resistance. CONCLUSIONS: A dramatic drop of HIV-1 drug resistance at failure has been achieved over the last two decades in Italy; resistance to three or more classes is low but present among currently failing patients. Its management still requires a rational and careful diagnostic and therapeutic approach.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Armenia D, Di Carlo D, Flandre P, et al. HIV MDR is still a relevant issue despite its dramatic drop over the years. J Antimicrob Chemother. 2020. PMID: 31976521. doi:10.1093/jac/dkz554

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。